Santen Pharmaceutical Co., Ltd. Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd.

4536

株式のランク #4341
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research,... Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
株価
$11.30
時価総額
$3.63B
変化(1日)
-0.35%
変化(1年)
-1.31%
国
JP
取引 Santen Pharmaceutical Co., Ltd. (4536)

カテゴリー

Healthcare
Santen Pharmaceutical Co., Ltd.(4536)のEPS
2026 時点のEPS TTM: 0
Santen Pharmaceutical Co., Ltd.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Santen Pharmaceutical Co., Ltd.のEPS履歴(2026から2026まで)
各年末時点のEPS
年 EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
$29.89 -
US
$6.60 -
US
$3.55 -
US
$1.26 -
US
$20.39 -
CH